This study is a randomized controlled trial, comparing the therapeutic effect of Azithromycin and Co-trimoxazole in the treatment of patients with ocular toxoplasmosis referred to Farabi eye hospital. Thirty patients are randomized 1:1 to each of the treatment groups. Clinical examination, Fundus photography, Autofluorescence and Infrared are performed before the treatment and in the third and sixth weeks after treatment and at the completion of therapy. Adverse effects of medications in both groups are registered. At the completion of treatment, the change in the size of lesions, improvement of visual acuity, medication side effects and vitreous changes will be compared between the two groups. Inclusion criteria were patients with ocular toxoplasmosis aged 15 years or above with positive anti-toxoplasma IgG antibody test. Exclusion criteria were pre-existing retinal diseases and antibiotic usage within the last three months.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT201401299820N5
Registration date:2014-03-11, 1392/12/20
Registration timing:registered_while_recruiting
Last update:
Update count:0
Registration date
2014-03-11, 1392/12/20
Registrant information
Name
Alireza Lashay
Name of organization / entity
Eye research center
Country
Iran (Islamic Republic of)
Phone
+98 21 5512 1002
Email address
lashay@tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Tehran University of Medical Of Siences
Expected recruitment start date
2013-10-23, 1392/08/01
Expected recruitment end date
2014-06-21, 1393/03/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of therapeutic effects of Azitromaycin and Cotrimoxazole in patients with ocular Toxoplasmosis .
Public title
Comparison of therapeutic effects of Azitromaycin and cotrimoxazole in patients with ocular toxoplasmosis .
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: patients with diagnosis of ocular toxoplasmosis with positive serologic test; patients older than 16 years old; no underline diseases(such as diabetic retinopathy or uveitis).
Exclusion criteria: patients under 16 years old; any related systemic or ocular diseases in particular immunodeficiency diseases.